+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

G

Actively Recruiting

Researchers are studying advanced non-small cell lung cancer NSCLC with a specific KRAS G12C gene mutation to see if adding the drug LY3537982 olomorasib to standard anti-cancer treatments provides better outcomes than standard treatment alone. This Phase 3 trial evaluates different combinations including pembrolizumab with or without chemotherapy. The study is sponsored by Eli Lilly and Company and aims to improve first-line treatment options for people with this type of lung cancer. Participants receive LY3537982 orally along with pembrolizumab intravenously in 21-day cycles. Some groups also receive chemotherapy drugs like pemetrexed and platinum agents cisplatin or carboplatin. There are various study parts including dose optimization, safety lead-in, and randomized treatment arms comparing LY3537982 combinations to placebo with pembrolizumab, with or without chemotherapy. Treatment continues until certain discontinuation criteria are met. During the study, participants will have regular visits for assessments including tumor measurements, physical function, symptom questionnaires, and safety monitoring. Researchers will measure progression-free survival, treatment side effects, response rates, and quality of life over an estimated period of up to three years depending on individual progress. Participants will be closely monitored throughout to evaluate the effects and safety of the study drug combinations.

Age: 18Years +All GendersPhase 3
415 locations
S

Actively Recruiting

This research aims to evaluate the safety, effectiveness, and tolerability of two repetitive transcranial magnetic stimulation rTMS protocols targeting the dorsolateral prefrontal cortex to reduce depression symptoms in U.S. military members and veterans with a history of concussion or mild traumatic brain injury. The study uses a randomized, double-blind, Bayesian adaptive design to compare individualized connectome targeted accelerated intermittent Theta Burst Stimulation and scalp-targeted stimulation in this specific population. Participants are assigned randomly to one of three groups active rTMS with individualized connectome targeting, active rTMS with resting state functional MRI-based targeting, or a sham placebo rTMS group. These treatments are delivered as device-based brain stimulation therapies designed to assess their impact on depressive symptoms. The study includes an initial treatment phase followed by post-intervention assessments and a 6-month follow-up period. During the study, participants will undergo evaluations using the Montgomery-Asberg Depression Rating Scale to measure changes in depression symptoms from baseline through post-intervention and at 6 months. Additional assessments include self-reported depression scales, quality of life related to brain injury, PTSD symptoms, and brain connectivity via MRI scans. Researchers will monitor treatment compliance, adverse events, and overall safety throughout the trial, which lasts up to 6 months after final treatment.

Age: 18Years - 55YearsAll GendersPhase Not Applicable
3 locations
I

Actively Recruiting

Researchers are evaluating the feasibility of providing early access to mental healthcare during sarcoma treatment and how this early psychiatric care relates to depression, anxiety, postoperative outcomes, and patient satisfaction in patients undergoing surgery for musculoskeletal sarcoma. The study is a randomized pilot designed to provide insights into mental health support for these patients. The research is led by Memorial Sloan Kettering Cancer Center and focuses on both bone and soft tissue sarcoma cases. Participants will be randomly assigned to one of two groups the Early Psychiatric Referral group or the No Referral group. Those in the referral group will be directed to the MSK Department of Psychiatry and Behavioral Sciences, while those in the no referral group will receive no psychiatric referral as part of the study. Specific psychiatric treatments are not dictated by the study beyond the referral process. During the study, participants will attend scheduled visits over a period of two years, during which researchers will track how many complete these visits. Assessments will include mental health status related to depression and anxiety, surgical outcomes, and patient satisfaction. The study aims to monitor the impact of early psychiatric involvement on overall quality of life for patients receiving surgical treatment for sarcoma.

Age: 18Years +All GendersPhase Not Applicable
8 locations